NCT00554372 - A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

February 28, 2013

Conditions

Carcinoma, Hepatocellular

Interventions

GENETIC

JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)

Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.

Trial Locations (9)

15213

University of Pittsburgh Medical Center - Liver Cancer Center, Pittsburgh

43210

The Ohio State University, Columbus

55905

Mayo Clinic, Rochester

59101

Billings Clinic Cancer Center, Billings

92093

Moores UCSD Cancer Center, La Jolla

L8N 1Y3

McMaster University Medical Centre, Hamilton

Unknown

Pusan National University Hospital, Busan

Samsung Medical Center, Seoul

Shin Chon Severance Hospital / Yonsei University Medical Center, Seoul